Published on 22 Feb 2024 on Zacks via Yahoo Finance
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -1.49%. A quarter ago, it was expected that this company would post a loss of $0.65 per share when it actually produced a loss of $0.55, delivering a surprise of 15.38%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.